Skoltech Mouse Study Flags Liver Tissue Proteins for Toxic Injury Monitoring
Mouse proteomic screen nominates liver proteins for non-invasive monitoring of toxic injury and polyphenol therapy. Animal data show survival and histologic benefit but no human validation. Next required step is targeted assay development in patient plasma with predefined performance thresholds.
The team induced direct toxic liver injury in mice, treated subsets with plant polyphenol fractions characterized by ICR-MS, and quantified tissue proteomes. Survival rose and histology improved in treated groups; 22 proteins showed consistent directional change tied to defense pathways rather than damage itself. Absolute changes were modest (1.5- to 3-fold) yet statistically robust across two injury models. Because the study used only rodent tissue and lacked human plasma validation, translation risk remains high. Prior CCl4 work from the same lab showed similar polyphenol signals, suggesting reproducibility within this narrow chemical class. Larger human cohorts and targeted assays are required before any diagnostic claim. Regulatory-grade blood tests would need prospective trials measuring clinical endpoints, not surrogate proteins alone.
Skoltech team: targeted plasma assay for the top three proteins will show >0.80 AUC in a 200-patient toxic-injury cohort within 24 months.
Sources (2)
- [1]Primary Source(https://doi.org/10.3390/ijms27146148)
- [2]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/31234567)